Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 29, 2026

Virtu Financial (VIRT) Q4 2025 Earnings Transcript

View original at finance.yahoo.com
Virtu Financial (VIRT) Q4 2025 Earnings Transcript Image source: The Motley Fool. Date Jan. 29, 2026 at 8 a.m. ET Call participants Chief Executive Officer — Aaron Simons Chief Financial Officer — Cindy Lee Co-President and Co-Chief Operating Officer — Joseph Molluso Need a quote from a Motley Fool analyst?…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Added complexity in market space with different trading protocols is relative competitive advantage for Virtu

    80% confidence
  • Virtu generated 100% return on incremental capital in Q4, though doesn't expect this to always be the case

    80% confidence
  • Non-customer market making businesses performed very well, including global equities presence

    80% confidence
  • VES had record quarter with accelerating client engagement, new clients onboarding, and existing clients doing more business across all products and geographies

    80% confidence
  • Virtu will achieve capital growth through organic growth and incremental borrowings where prudent

    80% confidence
  • Incremental capital added and dynamic deployment had meaningful impact on Q4 results

    80% confidence
  • Virtu increased invested capital by $625 million in 2025, with $448 million in second half, while generating 100% average return

    80% confidence
  • Q4 performance driven by favorable operating environment with elevated realized volatility, VIX, and equity share volumes

    80% confidence
  • Virtu deployed pretty much all of the incremental $628 million in trading capital while maintaining substantial buffers in regulated entities

    80% confidence
  • Virtu will maintain quarterly dividend of $0.24 per share while continuing to expand capital base

    80% confidence
  • VES stated goal was $2 million per day through the cycle and is well on way to achieving it

    80% confidence
  • Virtu stated long-term goal of $10 million per day ANTI through the cycle

    80% confidence
  • ETF growth and electronification/tokenization is generally positive for Virtu's business

    80% confidence
  • Q4 2025 ANTI of $9.7 million per day was highest quarterly total since Q1 2021

    80% confidence
  • Virtu is not focusing on small number of growth initiatives but growing everywhere in the firm and responding dynamically to market opportunities

    80% confidence
  • Virtu plans to grow trading by investing in infrastructure, acquiring talent and expanding capital base, with growth being a broad effort across the firm

    80% confidence
  • Virtu is optimistic about prediction markets but being careful given lack of perfect regulatory or legal certainty

    80% confidence
  • VES reached seventh consecutive quarter of increased ANTI and high watermark since early 2022

    80% confidence
  • Expected long-term returns on capital in the 50-70% range, not 100%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com